× Industry Reports Services Press Release Contact us About us

APAC Monoclonal Antibodies Market size to reach $80 Bn by 2027

 Request a sample

APAC Monoclonal Antibodies Market size is poised to surpass USD 80 billion by 2027, according to a latest forecast report by Graphical Research.

Growing prevalence of cancer will majorly contribute to industry growth with significant amount of mAbs approved for the disease treatment. As per the GLOBOCAN 2020 data, the mortality rate associated with cancer in Asia is higher in comparison with incidence rate. High risk of mortality has driven cancer research in the region. Governments of various countries are collaboratively working to address increasing concern related to cancer deaths. For instance, the Cancer Research UK and the Indian government’s Department of Biotechnology, collaboratively launched a 5-year initiative to encourage a multidisciplinary research effort increasing treatment affordability for cancer. Thus, government support to therapy innovations will offer unprecedented opportunities to the monoclonal antibodies industry.

International, well-established pharmaceutical giants are continuously expanding their business in developing countries. Over past few years, these market leaders have identified untapped major markets in middle-income countries that will result in market expansion at faster pace. Large population base with increasing disease incidence rate has created penetration opportunities for mAb development companies. Thus, industry expansion in unrecognized developing areas having capability to adopt newer therapies and will thereby drive market growth in foreseeable future.

Humanized monoclonal antibodies segment held 31.7% revenue share in 2020 with the segment growth attributable to its advantages over original mouse mAbs. The benefits associated with these products include reduced immunogenicity of mAb; the human C region allowing functions of human effector and the increased serum half-life in humans. With the use of genetic engineering technologies, researchers have developed humanized mAbs having clinical applications in treatment of various diseases. Thus, continued research to enhance specificity and introduction of efficient products will escalate the product demand for humanized monoclonal antibodies in the coming years.

Browse detailed statistical insights from the report, “Asia Pacific Monoclonal Antibodies Market Forecast 2027 By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Clinics), Research Report, Country Outlook (Japan, China, India, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @

https://www.graphicalresearch.com/industry-insights/1894/asia-pacific-monoclonal-antibodies-market

Autoimmune diseases segment accounted for around 31% market share in 2020. Disease control with the use of mAb therapeutics has shown high success rate in past years. Along with reversal of acute paralytic disease, monoclonal antibodies also reduce the number of relapses in multiple sclerosis after the first attack. Recurrent disease prevalence will further increase the product demand. Monoclonal antibodies can be effectively used to manipulate immune system that has further boosted its use in treatment of autoimmune diseases. Thus, higher product adoption in disease treatment will support segment revenue growth in future.

Clinics segment was valued for around USD 6 billion revenue in 2020. Increasing use of mAb products in clinics with patient visits suffering from infectious and chronic diseases will positively impact the segment growth. Growing efforts towards facility expansion to increase accessibility to all patients in the region will influence the product sales in these facilities. Moreover, availability of skilled administrators and specialists in clinics will drive patient preference, thereby propelling the segment revenue growth in future.

India monoclonal antibodies industry is anticipated to progress at 17.5% CAGR during forecast period. High industry growth rate is attributable to increasing disease prevalence in the region. Along with prevalence of chronic diseases such as cancer and cardiovascular conditions, emergence of severe infectious pathogenic diseases including COVID-19 will positively benefit the product demand in the country. For instance, notable increase in number of COVID-19 cases has driven R&D to identify mAb potential in prevention and treatment. Regulatory authorities have approved some mAb therapeutics that reduces the risk of hospitalization and mortality in COVID-19 patients.

The APAC monoclonal antibodies market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:

Asia Pacific Market, By Type

  • Fully human
  • Humanized
  • Chimeric
  • Others

Asia Pacific Market, By Application

  • Oncology
  • Autoimmune diseases
  • Infectious diseases
  • Others

 Asia Pacific Market, By End-use

  • Hospitals
  • Clinics
  • Others

The above information has been provided for the following countries:

  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines